(Q53163495)

12 May 2018

title

Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. (English)

1 reference

12 May 2018

0 references

5

Ertan Mayatepek

1 reference

12 May 2018

author name string

Eva Thimm

1

1 reference

12 May 2018

Diran Herebian

2

1 reference

12 May 2018

Birgit Assmann

3

1 reference

12 May 2018

Dirk Klee

4

1 reference

12 May 2018

Ute Spiekerkoetter

6

1 reference

12 May 2018

publication date

10 November 2010

1 reference

12 May 2018

Molecular Genetics and Metabolism

published in

1 reference

12 May 2018

volume

102

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

122-125

1 reference

12 May 2018

Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Nontransplant treatment of tyrosinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

NTBC treatment in tyrosinaemia type I: long-term outcome in French patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Toxicity assessment of the herbicides sulcotrione and mesotrione toward two reference environmental microorganisms: Tetrahymena pyriformis and Vibrio fischeri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Tyrosinemia type II: nine cases of ocular signs and symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Outcome of tyrosinaemia type III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Pregnancy and tyrosinaemia type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Tyrosine promotes oxidative stress in cerebral cortex of young rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Tyrosinemia: computed tomography, magnetic resonance imaging, diffusion magnetic resonance imaging, and proton spectroscopy findings in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Brain Magnetic Resonance Imaging in Tyrosinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Adult psychosocial outcome in early-treated phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Development of intelligence in early treated phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

The effects of high phenylalanine concentrations on serotinin and catecholamine metabolism in the human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Increased Vigilance and Dopamine Synthesis by Large Doses of Tyrosine or Phenylalanine Restriction in Phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

An animal model of early-treated PKU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Tyrosine for depression: a double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.003

10.1016/J.YMGME.2010.11.003

7 January 2021

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018